New living evidence resource of human and non-human studies for early intervention and research prioritisation in anxiety, depression and psychosis

doi:10.1136/bmjment-2023-300759

. 2023 Jun;26(1):e300759.

doi: 10.1136/bmjment-2023-300759.

New living evidence resource of human and non-human studies for early intervention and research prioritisation in anxiety, depression and psychosis

Andrea Cipriani^{1

2

3}, Soraya Seedat⁴, Lea Milligan⁵, Georgia Salanti⁶, Malcolm Macleod⁷, Janna Hastings^{8

9}, James Thomas¹⁰, Susan Michie¹¹, Toshi A Furukawa¹², David Gilbert¹³, Karla Soares-Weiser¹⁴, Carmen Moreno¹⁵, Stefan Leucht¹⁶, Matthias Egger^{6

17

18}, Parisa Mansoori⁵, James M Barker¹⁹, Spyridon Siafis¹⁶, Edoardo Giuseppe Ostinelli^{20

2}, Robert McCutcheon^{20

3

21}, Simonne Wright⁴, Matilda Simpson⁵, Olufisayo Elugbadebo^{4

22}, Virginia Chiocchia⁶, Thomy Tonia⁶, Rania Elgarf^{20

2}, Ayse Kurtulmus²³, Emily Sena⁷, Ouma Simple^{4

24}, Niall Boyce²⁵, Sophie Chung²⁵, Anjuli Sharma²⁵, Miranda Wolpert²⁵, Jennifer Potts^{20

2}, Julian H Elliott^{26

27}

Affiliations

¹ Department of Psychiatry, University of Oxford, Oxford, UK andrea.cipriani@psych.ox.ac.uk.
² Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre, Oxford, UK.
³ Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.
⁴ South African Medical Research Council/Stellenbosch University Extramural Genomics of Brain Disorders Unit, Department of Psychiatry, Stellenbosch University, Cape Town, South Africa.
⁵ MQ, Mental Health Research, London, UK.
⁶ Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
⁷ Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
⁸ Institute for Implementation Science in Health Care, Faculty of Medicine, University of Zurich, Zurich, Switzerland.
⁹ School of Medicine, University of St. Gallen, St. Gallen, Switzerland.
¹⁰ EPPI Centre, Social Research Institute, University College London, London, UK.
¹¹ UCL Centre for Behaviour Change, University College London, London, UK.
¹² Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine / School of Public Health, Kyoto, Japan.
¹³ Chair, GALENOS Global Experiential Advisory Board, InHealth Associates, London, UK.
¹⁴ Cochrane, London, UK.
¹⁵ Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, ISCIII, School of Medicine, Universidad Complutense, Madrid, Spain.
¹⁶ Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.
¹⁷ Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
¹⁸ Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
¹⁹ F1000, Research Ltd, London, UK.
²⁰ Department of Psychiatry, University of Oxford, Oxford, UK.
²¹ Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK.
²² Department of Psychiatry, University of Ibadan, Ibadan, Nigeria.
²³ Department of Psychiatry, Istanbul Medeniyet University, Turkey, Turkey.
²⁴ College of Health Sciences, Makerere University, Kampala, Uganda.
²⁵ Wellcome, London, UK.
²⁶ Cochrane Australia, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
²⁷ Future Evidence Foundation, Melbourne, Victoria, Australia.

PMID: 37290906
PMCID: PMC10255027
DOI: 10.1136/bmjment-2023-300759

New living evidence resource of human and non-human studies for early intervention and research prioritisation in anxiety, depression and psychosis

Andrea Cipriani et al. BMJ Ment Health. 2023 Jun.

. 2023 Jun;26(1):e300759.

doi: 10.1136/bmjment-2023-300759.

Authors

Affiliations

¹ Department of Psychiatry, University of Oxford, Oxford, UK andrea.cipriani@psych.ox.ac.uk.
² Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre, Oxford, UK.
³ Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.
⁴ South African Medical Research Council/Stellenbosch University Extramural Genomics of Brain Disorders Unit, Department of Psychiatry, Stellenbosch University, Cape Town, South Africa.
⁵ MQ, Mental Health Research, London, UK.
⁶ Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
⁷ Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
⁸ Institute for Implementation Science in Health Care, Faculty of Medicine, University of Zurich, Zurich, Switzerland.
⁹ School of Medicine, University of St. Gallen, St. Gallen, Switzerland.
¹⁰ EPPI Centre, Social Research Institute, University College London, London, UK.
¹¹ UCL Centre for Behaviour Change, University College London, London, UK.
¹² Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine / School of Public Health, Kyoto, Japan.
¹³ Chair, GALENOS Global Experiential Advisory Board, InHealth Associates, London, UK.
¹⁴ Cochrane, London, UK.
¹⁵ Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, ISCIII, School of Medicine, Universidad Complutense, Madrid, Spain.
¹⁶ Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.
¹⁷ Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
¹⁸ Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
¹⁹ F1000, Research Ltd, London, UK.
²⁰ Department of Psychiatry, University of Oxford, Oxford, UK.
²¹ Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK.
²² Department of Psychiatry, University of Ibadan, Ibadan, Nigeria.
²³ Department of Psychiatry, Istanbul Medeniyet University, Turkey, Turkey.
²⁴ College of Health Sciences, Makerere University, Kampala, Uganda.
²⁵ Wellcome, London, UK.
²⁶ Cochrane Australia, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
²⁷ Future Evidence Foundation, Melbourne, Victoria, Australia.

PMID: 37290906
PMCID: PMC10255027
DOI: 10.1136/bmjment-2023-300759

Abstract

In anxiety, depression and psychosis, there has been frustratingly slow progress in developing novel therapies that make a substantial difference in practice, as well as in predicting which treatments will work for whom and in what contexts. To intervene early in the process and deliver optimal care to patients, we need to understand the underlying mechanisms of mental health conditions, develop safe and effective interventions that target these mechanisms, and improve our capabilities in timely diagnosis and reliable prediction of symptom trajectories. Better synthesis of existing evidence is one way to reduce waste and improve efficiency in research towards these ends. Living systematic reviews produce rigorous, up-to-date and informative evidence summaries that are particularly important where research is emerging rapidly, current evidence is uncertain and new findings might change policy or practice. Global Alliance for Living Evidence on aNxiety, depressiOn and pSychosis (GALENOS) aims to tackle the challenges of mental health science research by cataloguing and evaluating the full spectrum of relevant scientific research including both human and preclinical studies. GALENOS will also allow the mental health community-including patients, carers, clinicians, researchers and funders-to better identify the research questions that most urgently need to be answered. By creating open-access datasets and outputs in a state-of-the-art online resource, GALENOS will help identify promising signals early in the research process. This will accelerate translation from discovery science into effective new interventions for anxiety, depression and psychosis, ready to be translated in clinical practice across the world.

Keywords: Adult psychiatry; Anxiety disorders; Child & adolescent psychiatry; Depression & mood disorders; Schizophrenia & psychotic disorders.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AC received research, educational and consultancy fees from the Italian Network for Paediatric Trials, CARIPLO Foundation, Lundbeck, and Angelini Pharma. RM received speaker/consultancy fees from Karuna, Janssen, Boehringer Ingelheim and Otsuka, and is director of a company that hosts psychotropic prescribing decision tools. TAF reports personal fees from Boehringer-Ingelheim, DT Axis, Kyoto University Original, Shionogi and SONY, and a grant from Shionogi outside the submitted work; in addition, TAF has patents 2020-548587 and 2022-082495 pending, and intellectual properties for Kokoro-app licensed to Mitsubishi-Tanabe. CM received honoraria as a consultant and/or advisor and/or for lectures from Angelini, Compass, Esteve, Exeltis Janssen, Lundbeck, Neuraxpharm, Nuvelution, Otsuka, Pfizer, Servier and Sunovion outside the submitted work. EGO has received research and consultancy fees from Angelini Pharma. In the last three years SL has received honoraria as a consultant and/or advisor and/or for lectures and/or for educational material from Alkermes, Angelini, Eisai, Gedeon Richter, Janssen, Lundbeck, Medichem, Medscape, Merck Sharpp and Dome, Mitshubishi, Neurotorium, NovoNordisk, Otsuka, Recordati, Roche, Rovi, Sanofi Aventis, TEVA.

Figures

**Figure 1**
Global Alliance for Living Evidence on Anxiety, Depression and Psychosis organisational structure: leadership group, advisory boards and four interconnected WPs. WP, work package.

**Figure 2**
Global Alliance for Living Evidence on Anxiety, Depression and Psychosis: a global resource curated by a global community.

See this image and copyright information in PMC

Cited by

Development and evaluation of prompts for a large language model to screen titles and abstracts in a living systematic review.
Homiar A, Thomas J, Ostinelli EG, Kennett J, Friedrich C, Cuijpers P, Harrer M, Leucht S, Miguel C, Rodolico A, Kataoka Y, Takayama T, Yoshimura K, So R, Tsujimoto Y, Yamagishi Y, Takagi S, Sakata M, Bašić Đ, Karyotaki E, Potts J, Salanti G, Furukawa TA, Cipriani A. Homiar A, et al. BMJ Ment Health. 2025 Jul 22;28(1):e301762. doi: 10.1136/bmjment-2025-301762. BMJ Ment Health. 2025. PMID: 40701625 Free PMC article.
Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and meta-analysis of human and non-human studies.
Siafis S, McCutcheon R, Chiocchia V, Ostinelli EG, Wright S, Stansfield C, Juma DO, Mantas I, Howes OD, Rutigliano G, Ramage F, Tinsdeall F, Friedrich C, Milligan L, Moreno C, Elliott JH, Thomas J, Macleod MR, Sena ES, Seedat S, Salanti G, Potts J, Cipriani A, Leucht S; GALENOS team. Siafis S, et al. Wellcome Open Res. 2023 Aug 25;8:365. doi: 10.12688/wellcomeopenres.19866.1. eCollection 2023. Wellcome Open Res. 2023. PMID: 38634067 Free PMC article.
The therapeutic potential of exercise in post-traumatic stress disorder and its underlying mechanisms: A living systematic review of human and non-human studies.
Wright S, Chiocchia V, Elugbadebo O, Simple O, Furukawa TA, Friedrich C, Austin C, Dehdarirad H, Gilbert D, Kennett J, Ostinelli EG, Potts J, Ramage F, Sena E, Siafis S, Stansfield C, Thomas J, Tinsdeall F, Tonia T, Macleod M, Cipriani A, Salanti G, Seedat S. Wright S, et al. Wellcome Open Res. 2025 May 27;9:720. doi: 10.12688/wellcomeopenres.23033.4. eCollection 2024. Wellcome Open Res. 2025. PMID: 40171151 Free PMC article.
Assessing the Impact of Evidence-Based Mental Health Guidance During the COVID-19 Pandemic: Systematic Review and Qualitative Evaluation.
Smith KA, Ostinelli EG, Ede R, Allard L, Thomson M, Hewitt K, Brown P, Zangani C, Jenkins M, Hinze V, Ma G, Pothulu P, Henshall C, Malhi GS, Every-Palmer S, Cipriani A. Smith KA, et al. JMIR Ment Health. 2023 Dec 22;10:e52901. doi: 10.2196/52901. JMIR Ment Health. 2023. PMID: 38133912 Free PMC article.
Public involvement in an aggregate and individual participant data meta-analysis of mindfulness-based programmes for mental health promotion.
Friedrich C, Fairbairn T, Denton G, Geddes M, Thomas-Carr D, Jones PB, Galante J. Friedrich C, et al. Syst Rev. 2024 Aug 6;13(1):212. doi: 10.1186/s13643-024-02601-5. Syst Rev. 2024. PMID: 39107829 Free PMC article.

See all "Cited by" articles

References

1. GBD 2019 Mental Disorders Collaborators . Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 2022;9:137–50. 10.1016/S2215-0366(21)00395-3 - DOI - PMC - PubMed
1. Gartlehner G, Dobrescu A, Chapman A, et al. . Nonpharmacologic and pharmacologic treatments of adult patients with major depressive disorder: a systematic review and network meta-analysis for a clinical guideline by the American College of Physicians. Ann Intern Med 2023;176:196–211. 10.7326/M22-1845 - DOI - PubMed
1. Gardner C, Kleinman A. Medicine and the mind – the consequences of psychiatry’s identity crisis. N Engl J Med 2019;381:1697–9. 10.1056/NEJMp1910603 - DOI - PubMed
1. Lan DCL, Browning M. What can reinforcement learning models of dopamine and serotonin tell us about the action of antidepressants Computational Psychiatry 2022;6:166–88. 10.5334/cpsy.83 - DOI - PMC - PubMed
1. The best research is produced when researchers and communities work together. Nature 2018;562:7. 10.1038/d41586-018-06855-7 - DOI - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] GBD 2019 Mental Disorders Collaborators . Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 2022;9:137–50. 10.1016/S2215-0366(21)00395-3 - DOI - PMC - PubMed

[2] GBD 2019 Mental Disorders Collaborators . Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 2022;9:137–50. 10.1016/S2215-0366(21)00395-3 - DOI - PMC - PubMed

[3] Gartlehner G, Dobrescu A, Chapman A, et al. . Nonpharmacologic and pharmacologic treatments of adult patients with major depressive disorder: a systematic review and network meta-analysis for a clinical guideline by the American College of Physicians. Ann Intern Med 2023;176:196–211. 10.7326/M22-1845 - DOI - PubMed

[4] Gartlehner G, Dobrescu A, Chapman A, et al. . Nonpharmacologic and pharmacologic treatments of adult patients with major depressive disorder: a systematic review and network meta-analysis for a clinical guideline by the American College of Physicians. Ann Intern Med 2023;176:196–211. 10.7326/M22-1845 - DOI - PubMed

[5] Gardner C, Kleinman A. Medicine and the mind – the consequences of psychiatry’s identity crisis. N Engl J Med 2019;381:1697–9. 10.1056/NEJMp1910603 - DOI - PubMed

[6] Gardner C, Kleinman A. Medicine and the mind – the consequences of psychiatry’s identity crisis. N Engl J Med 2019;381:1697–9. 10.1056/NEJMp1910603 - DOI - PubMed

[7] Lan DCL, Browning M. What can reinforcement learning models of dopamine and serotonin tell us about the action of antidepressants Computational Psychiatry 2022;6:166–88. 10.5334/cpsy.83 - DOI - PMC - PubMed

[8] Lan DCL, Browning M. What can reinforcement learning models of dopamine and serotonin tell us about the action of antidepressants Computational Psychiatry 2022;6:166–88. 10.5334/cpsy.83 - DOI - PMC - PubMed

[9] The best research is produced when researchers and communities work together. Nature 2018;562:7. 10.1038/d41586-018-06855-7 - DOI - PubMed

[10] The best research is produced when researchers and communities work together. Nature 2018;562:7. 10.1038/d41586-018-06855-7 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

New living evidence resource of human and non-human studies for early intervention and research prioritisation in anxiety, depression and psychosis

Affiliations

New living evidence resource of human and non-human studies for early intervention and research prioritisation in anxiety, depression and psychosis

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

MeSH terms

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical